Huntington Ingalls, Crocs, Carvana, Insmed and other big stocks moving higher on Thursday
U.S. stocks were lower, with the Dow Jones falling around 150 points on Thursday. Shares of Huntington Ingalls Industries Inc ...
Model output · Signal date 2026-11-10
Insmed Inc (INSM) Stock Forecast Nov. 10, 2026
Analysis updated on Nov. 10, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
of 4224 stocks scored
Rank correlation · 90D
41.0%
Spearman, 358 dates
Market Cap
$25.47B
large-cap · #22 of 60 peers
Summary
Insmed Inc (INSM) stock forecast summary
Our AI scores Insmed Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Insmed Inc is a large-cap company with a market capitalization of $25.47B. It ranks number 22 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For INSM, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 41.0%, measured on 358 forecast dates between 2022-08-23 and 2026-08-12 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 21.0%, measured on 400 forecast dates between 2022-08-23 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +6.4%, buy ≥ +4.3%, sell < +2.2%, strong sell < +0.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-09 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, INSM included.
Price
INSM price chart and AI forecast
Cross-section · 2026-11-09
How INSM ranks among 4224 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-09-30
Insmed Inc (INSM) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | INSM | Rank |
|---|---|---|
| Market Cap | $25.47B | 22/60 |
| P/B Ratio | 35.07x | 5/42 |
| EPS | $-2.01 | – |
| Book Value/Share | $3.31 | – |
| Revenue/Share | $6.93 | – |
| FCF/Share | $-2.86 | – |
Profitability & Margins
| Metric | INSM | Rank |
|---|---|---|
| ROE | -83.4% | 33/39 |
| ROA | -27.2% | 37/43 |
| ROIC | -34.6% | 37/44 |
| Gross Margin | 84.4% | 14/36 |
| Operating Margin | -37.1% | 31/38 |
| Net Margin | -39.9% | 28/35 |
| EBT Margin | -39.4% | 38/46 |
| Tax Rate | -1.3% | – |
Financial Health
| Metric | INSM | Rank |
|---|---|---|
| Current Ratio | 2.86x | 26/58 |
| Quick Ratio | 2.59x | 12/43 |
| D/E Ratio | 2.07x | 11/47 |
| Financial Leverage | 3.07x | 9/47 |
| Interest Coverage | -6.7x | 22/33 |
| Working Capital | $1.11B | 23/58 |
Cash Flow
| Metric | INSM | Rank |
|---|---|---|
| Operating Cash Flow | -$596M | 59/59 |
| Free Cash Flow | -$628M | 50/50 |
| Capital Spending | -$32M | 24/50 |
| FCF/Sales | -41.3% | 39/42 |
| CapEx/Sales | 2.1% | 25/42 |
Operational Efficiency
| Metric | INSM | Rank |
|---|---|---|
| Asset Turnover | 0.68x | 11/39 |
| Receivables Turnover | 5.9x | 12/36 |
| Inventory Turnover | 1.4x | 19/35 |
| Fixed Assets Turnover | 14.0x | 15/41 |
| Days Sales Outstanding | 62 days | 25/36 |
| Days Inventory | 252 days | 17/35 |
| Payables Period | 130 days | 12/24 |
| Cash Conversion Cycle | 185 days | 12/22 |
Income Statement
| Metric | INSM | Rank |
|---|---|---|
| Total Revenue | $1.52B | 27/46 |
| Operating Income | -$564M | 47/50 |
| Net Income | -$606M | 42/47 |
| R&D Expense | $944M | 21/58 |
| SG&A Expense | $960M | 24/40 |
| Cost of Goods Sold | $237M | 27/37 |
Dividend & Shareholder Information
| Metric | INSM | Rank |
|---|---|---|
| Shares Outstanding | 219M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.71B | 76.7% of assets |
| Cash & Short-term Investments | $397M | 17.8% of assets |
| Accounts Receivable | $259M | 11.6% of assets |
| Inventory | $164M | 7.4% of assets |
| Total Liabilities | $1.50B | 67.4% of assets |
| Short-term Debt | $512M | 23.0% of assets |
Quarterly Financial Reports
INSM quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Insmed Inc (INSM) industry peers
Companies classified under the same SEC industry code as Insmed Inc (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| INSM Insmed Inc | $25.47B | |
| LLY Eli Lilly & Co | $1.33T | |
| JNJ Johnson & Johnson | $679.13B | |
| ABBV Abbvie Inc. | $518.30B | |
| MRK Merck & Co., Inc. | $367.02B | |
| NVS Novartis Ag | $312.35B | |
| AZN Astrazeneca Plc | $293.55B | |
| ABT Abbott Laboratories | $192.16B | |
| NVO Novo Nordisk A S | $183.89B | |
| PFE Pfizer Inc | $166.60B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $139.62B | |
| BMY Bristol Myers Squibb Co | $127.02B | |
| SNY Sanofi | $118.63B | |
| GSK Gsk Plc | $103.98B | |
| REGN Regeneron Pharmaceuticals, Inc. | $94.71B | |
| TAK Takeda Pharmaceutical Co Ltd | $65.88B | |
| TEVA Teva Pharmaceutical Industries Ltd | $50.07B | |
| ONC Beone Medicines Ltd. | $47.44B | |
| GMAB Genmab A/S | $35.90B | |
| ZTS Zoetis Inc. | $34.02B | |
| RPRX Royalty Pharma Plc | $29.45B | |
| ROIV Roivant Sciences Ltd. | $29.38B | |
| UTHR United Therapeutics Corp | $24.98B | |
| VTRS Viatris Inc | $23.53B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.98B | |
| ASND Ascendis Pharma A/S | $17.07B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.81B | |
| BBIO Bridgebio Pharma, Inc. | $15.18B | |
| SMMT Summit Therapeutics Inc. | $14.23B | |
| ELAN Elanco Animal Health Inc | $13.41B | |
| RDY Dr Reddys Laboratories Ltd | $12.56B | |
| BMRN Biomarin Pharmaceutical Inc | $11.07B | |
| TGTX Tg Therapeutics, Inc. | $10.06B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $10.00B | |
| SYRE Spyre Therapeutics, Inc. | $9.61B | |
| PRAX Praxis Precision Medicines, Inc. | $9.30B | |
| PTGX Protagonist Therapeutics, Inc | $8.79B | |
| CORT Corcept Therapeutics Inc | $8.11B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.85B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.76B | |
| ALKS Alkermes Plc. | $7.75B | |
| CYTK Cytokinetics Inc | $7.67B | |
| AXSM Axsome Therapeutics, Inc. | $7.02B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $6.96B | |
| ORKA Oruka Therapeutics, Inc. | $6.92B | |
| ABVX Abivax S.A. | $6.83B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.80B | |
| LGND Ligand Pharmaceuticals Inc | $6.28B | |
| BLTE Belite Bio, Inc | $6.20B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.05B | |
| MANE Veradermics, Inc | $6.01B | |
| COGT Cogent Biosciences, Inc. | $5.82B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| ERAS Erasca, Inc. | $5.46B | |
| PTCT Ptc Therapeutics, Inc. | $5.43B | |
| EWTX Edgewise Therapeutics, Inc. | $5.29B | |
| IONS Ionis Pharmaceuticals Inc | $5.15B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $5.03B | |
| TVTX Travere Therapeutics, Inc. | $4.62B | |
| LEGN Legend Biotech Corp | $4.49B |
Where INSM sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Insmed Inc (INSM) stock news
Insmed (INSM) Hits All-Time High as Firm Posts Highly Optimistic Outlook
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Insmed Inc (INSM) Q3 2026 Earnings Call Highlights: Brinsupri Hits Blockbuster Status as ...
Insmed Inc (INSM) raised full-year guidance for both Brinsupri and Arikayce while projecting over $14 billion in combined peak sales across its three lead respiratory assets.
FAQ
Insmed Inc (INSM) stock forecast FAQ
What is the Insmed Inc (INSM) stock forecast?
Our AI scores Insmed Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Insmed Inc stock predictions?
For INSM, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 41.0%, measured on 358 forecast dates between 2022-08-23 and 2026-08-12 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 21.0%, measured on 400 forecast dates between 2022-08-23 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Insmed Inc forecasts updated?
Insmed Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 10, 2026.
Which companies are Insmed Inc's industry peers?
60 issuers in our coverage, INSM included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.